@article{58020eb54b4c4aac882090d786d56817,
title = "Deep Brain Stimulation for Depression Informed by Intracranial Recordings",
abstract = "The success of deep brain stimulation (DBS) for treating Parkinson's disease has led to its application to several other disorders, including treatment-resistant depression. Results with DBS for treatment-resistant depression have been heterogeneous, with inconsistencies largely driven by incomplete understanding of the brain networks regulating mood, especially on an individual basis. We report results from the first subject treated with DBS for treatment-resistant depression using an approach that incorporates intracranial recordings to personalize understanding of network behavior and its response to stimulation. These recordings enabled calculation of individually optimized DBS stimulation parameters using a novel inverse solution approach. In the ensuing double-blind, randomized phase incorporating these bespoke parameter sets, DBS led to remission of symptoms and dramatic improvement in quality of life. Results from this initial case demonstrate the feasibility of this personalized platform, which may be used to improve surgical neuromodulation for a vast array of neurologic and psychiatric disorders.",
keywords = "Deep brain stimulation, Depression, Epilepsy, Network, Neuromodulation, Stereo-EEG",
author = "Sheth, {Sameer A.} and Bijanki, {Kelly R.} and Brian Metzger and Anusha Allawala and Victoria Pirtle and Adkinson, {Joshua A.} and John Myers and Mathura, {Raissa K.} and Denise Oswalt and Evangelia Tsolaki and Jiayang Xiao and Angela Noecker and Strutt, {Adriana M.} and Cohn, {Jeffrey F.} and McIntyre, {Cameron C.} and Mathew, {Sanjay J.} and David Borton and Wayne Goodman and Nader Pouratian",
note = "Funding Information: This work was supported by the National Institutes of Health (Grant No. UH3 NS103549 [to SAS, KB, AA, VP, JAA, BM, JM, RM, DO, ET, AMS, JFC, SJM, DB, WG, and NP], Grant No. R01 MH106700 [to SAS], Grant Nos. UH3 NS100549 and R01 MH114854 [to WG], Grant No. UH3 NS100549 [to JFC], Grant Nos. K01 MH116364 and R21 NS104953 [to KB and BM], and Grant No. R01 NS105690 [to CCM and AMN]), the McNair Foundation (to SAS), and the Dana Foundation (to SAS). Funding Information: This work was supported by the National Institutes of Health (Grant No. UH3 NS103549 [to SAS, KB, AA, VP, JAA, BM, JM, RM, DO, ET, AMS, JFC, SJM, DB, WG, and NP], Grant No. R01 MH106700 [to SAS], Grant Nos. UH3 NS100549 and R01 MH114854 [to WG], Grant No. UH3 NS100549 [to JFC], Grant Nos. K01 MH116364 and R21 NS104953 [to KB and BM], and Grant No. R01 NS105690 [to CCM and AMN]), the McNair Foundation (to SAS), and the Dana Foundation (to SAS). SAS, NP, and WG wrote the grant. SAS, NP, WG, SJM, DB, KB, and JFC oversaw organization of the trial, subject recruitment, regulatory activities, and data analysis. AN and CCM provided the holographic planning support. AMS conducted neuropsychological assessments. AA, VP, JAA, BM, JM, RM, DO, and ET carried out the recording and stimulation and collected and analyzed data. SAS, NP, and KB wrote the manuscript. All authors edited the manuscript and agree with its contents. SAS, NP, WG, and KB have verified the underlying data. We thank Mark Griswold, Jeff Mlakar, and the Interactive Commons at Case Western Reserve University for contributions to the holographic surgical planning. SAS is a consultant for Boston Scientific, Neuropace, Abbott, and Zimmer Biomet. NP is a consultant for Boston Scientific and Abbott. WG has received donated devices from Medtronic and is a consultant for Biohaven Pharmaceuticals. SJM has served as a consultant for Alkermes, Allergan, Axsome Therapeutics, Clexio Biosciences, Engrail Therapeutics, Intra-Cellular Therapies, Janssen, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, and Sage Therapeutics. CCM is a consultant for Boston Scientific; receives royalties from Hologram Consultants, Neuros Medical, and Qr8 Health; and is a shareholder in the following companies: Hologram Consultants, Surgical Information Sciences, CereGate, Autonomic Technologies, Cardionomic, Enspire DBS. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: {\textcopyright} 2021 Society of Biological Psychiatry",
year = "2022",
doi = "10.1016/j.biopsych.2021.11.007",
language = "English (US)",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
}